In vitro & ex vivo services
OITL provides a broad range of in vitro and ex vivo assay solutions to support the development and validation of novel radiopharmaceuticals
In vitro services
With extensive experience in molecular and cell biology and immunology, we excel in designing, developing and characterizing advanced in vitro model systems to drive innovative diagnostic and therapeutic solutions.
As a registered purchaser of ATCC and DSMZ, we have access to an extensive selection of cell lines, enabling us to develop a wide range of cell-derived and patient-derived xenograft models tailored to your specific research needs. We specialize in developing new molecules, analyzing target specificity, identifying potential off-target interactions, and designing functional assays.
Our comprehensive service portfolio includes the following in vitro techniques:
- Cell culture and cell isolations
- Cytotoxicity assays
- Cell proliferation & viability assays
- Reporter gene assays (luciferase, GFP)
- Cell migration & invasion assays
- 3D cell culture assays (spheroids, organoids)
- Receptor binding assays
- ELISA
- Western blotting
- Expanded molecular techniques including PCR, qPCR and cloning
Ex vivo services
To strengthen the evaluation of the pharmacokinetic profile and target engagement of your novel drug candidate, OITL offers service in ex vivo studies.
We perform quantitative assessment of the uptake of radiopharmaceuticals in organs and tissues of interest. This provides detailed insights into tissue-specific accumulation, microdistribution, off-target accumulation, and pharmacokinetics (cut-and-count).
Ex vivo capabilities:
- Tissue handling and preservation
- Biodistribution studies
- Autoradiography
- Immunohistochemistry
- Antibody-dependent cell-mediated cytotoxicity (ADCC)
- ELISPOT assays
- Flow cytometry
If you would like to learn more about our in vitro and ex vivo services and expertise, feel free to reach out and discuss your project with us.